Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.

Additional Metadata
Persistent URL dx.doi.org/10.1016/j.drudis.2016.05.012, hdl.handle.net/1765/90921
Journal Drug Discovery Today
Citation
de Marchi, T, Foekens, J.A, Umar, A, & Martens, J.W.M. (2016). Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discovery Today (Vol. 21, pp. 1181–1188). doi:10.1016/j.drudis.2016.05.012